Research progress on immune microenvironment and biomarkers of small cell lung cancer Authors: Na Di, Heping Sun, Qi Wang, Rui Zhong, Lin Tian, Peiyan Zhao, Hui Li, Haifeng Liu Published: 2026 ABSTRACT Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases. SCLC is characterized by rapid proliferation, early distant metastasis, high recurrence rate, and poor prognosis, with a 5-year survival rate of less than 7%. Immune checkpoint inhibitor (ICI)-based immunotherapy has been widely applied in SCLC clinical practice, including immunotherapy combined with chemotherapy as first-line therapy, tarlatamab (post-chemo/immunotherapy) and lurbinectedin (post-platinum chemotherapy) as later-line options for extensive-stage SCLC (ES-SCLC), and chemoradiotherapy (CRT) followed by consolidation of immune therapy for limited-stage SCLC (LS-SCLC). However, the efficacy of immune combination therapy in SCLC patients remains limited and studies confirmed that objective response rate (ORR) of first-line immunochemotherapy in advanced SCLC is approximately 60–70%, while the durable response rate remains only 10–20%. The main reason lies in the complex and heterogeneous immune microenvironment of SCLC, where a network of immunosuppressive factors orchestrates an immune-excluded or “cold” phenotype. With the development of genomics application in SCLC research, increasing data have revealed and validated the immune microenvironment features of SCLC. However, there is a lack of systematic reviews in this field. This review focuses on clinical translational research across SCLC stages and subtypes, systematically summarizing the immune microenvironment features of LS-SCLC, ES-SCLC, recurrent/relapse SCLC, and never-smoker SCLC (nsSCLC) by integrating data generated from genomic sequencing, single-cell sequencing, spatial transcriptomics, and other research approaches. We summarize the biological and immune features of SCLC and highlight key biomarkers, with the goal of offering new perspectives to improve immunotherapy outcomes and uncover novel therapeutic vulnerabilities. Introduction Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer worldwide (1) and possesses the features of deadly malignancies including rapid proliferation, early distant metastasis and poor prognosis, with a 5-year survival rate of less than 7% (2). Based on the radiation field, SCLC is classified into limited-stage SCLC (LS-SCLC) and extensive-stage SCLC (ES-SCLC), and the latter accounts for 75% of all SCLC patients (3). The advent of immunotherapy has transformed treatment landscape of SCLC and improved survival outcomes (4). Phase III ADRIATIC trial established durvalumab consolidation as a new standard of care for LS-SCLC, significantly improving overall survival (OS) with 55.9 vs. 33.4 months and hazard ratio (HR) =0.73 (5). For ES-SCLC, the first-line maintenance setting has seen a breakthrough with the phase III IMforte trial, which demonstrated that lurbinectedin plus atezolizumab as maintenance therapy significantly prolonged progression-free survival (PFS) and OS (5.4 vs. 2.1 months, HR =0.54; 13.2 vs. 10.6 months, HR =0.73) compared with atezolizumab alone, establishing a novel first-line maintenance option for ES-SCLC (6). In the second-line setting, the DeLLphi-304 trial confirmed tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, as a superior second-line option, significantly prolonging OS compared with standard chemotherapy (13.6 vs. 8.3 months, HR =0.60) and ushering in a ‘chemotherapy-free’ era (7). Furthermore, the emergence of next-generation immunotherapies, including novel antibody-drug conjugates (ADCs), B7-H3-targeted ifinatamab deruxtecan, SEZ6-targeted ABBV-706, as well as chimeric antigen receptor T-cell (CAR-T) and radiopharmaceuticals, is reshaping the treatment landscape and addressing the challenge of immunotherapy resistance (8-10). These emerging modalities, alongside established immunotherapies, are reshaping the treatment paradigm and will be discussed in detail in subsequent sections. Durvalumab as consolidation therapy in LS-SCLC (11), immunochemotherapy as first-line and immunotherapy combined with lurbinectedin as maintenance therapy for ES-SCLC (12), as well as tarlatamab for recurrent SCLC, symbolize the robust efficacy of immunotherapy in SCLC clinical practice (13). However, the survival advantage of immunotherapy in SCLC is limited, as evidenced by low proportion of patients who respond to this treatment (14). Studies revealed that SCLC is an immune-cold tumor and the immune microenvironment is complex, diverse, and highly heterogeneous (15). The development of multi-omics has been providing more data to facilitate us to draw a more vivid picture to understand more deeply and thoroughly the detailed knowledge of immune microenvironment and biomarkers from most cutting-edge frontiers (16). The immune microenvironment landscape of SCLC The immune microenvironment of SCLC is specific and differs from that of most solid tumors. Its immune characteristics mainly include a high degree of immunosuppression, strong spatial heterogeneity, and significant subtype specificity (17). The complex composition directly influences tumor progression and response to immunotherapy (18). At the cellular composition level, most solid tumors are classified as “hot tumors” or “semi-hot tumors” (19). Effector immune cells [such as CD8+ T-cells and dendritic cells (DCs)] can directly infiltrate tumor nests, with relatively sufficient T-cell numbers and a certain anti-tumor activity (20). However, SCLC is a typical “cold tumor” (21), exhibiting both spatial and functional immune barriers. Effector immune cells such as CD8+ T-cells and natural killer (NK) cells are scarce and largely confined to tumor margin, unable to penetrate the nests. Furthermore, limited infiltrating CD8+ cytotoxic T lymphocytes often undergo functional exhaustion due to chronic antigen exposure and immunosuppressive signaling (22). Meanwhile, the proportion of immunosuppressive cells [such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)] significantly increases, further weakening the immune response (22-24). The number of anti-presenting cells is reduced and their function is exhausted, failing to effectively capture, process and present tumor antigens and activate T-cells, leading to impaired initiation of immune responses (25). For certain solid tumors (such as breast cancer), although molecular subtypes correlate with the immune microenvironment, this correlation is weak, immune characteristics thus vary considerably among patients within the same subtype (26). At the molecular regulation level, despite low programmed death-ligand 1 (PD-L1) expression in SCLC, PD-L1 inhibitors combined with chemotherapy have become first-line standard treatment for ES-SCLC. Both CASPIAN and IMpower133 studies confirmed that this regimen significantly prolongs OS of patients, but effective predictive biomarkers are lacking. Liu et al. and Chen et al. (27,28) revealed that ZFHX3 gene mutations are associated with increased immune cell infiltration levels in SCLC, and patients carrying this mutation show better response to programmed cell death protein 1 (PD-1)/PD-L1 inhibitor combined with chemotherapy. At the molecular regulation level, mounting evidence indicates that various epigenetic regulators enforce immune invisibility in SCLCs. Enhancer of zeste homolog 2 (EZH2), a catalytic component of polycomb repressive complex 2 (PRC2) CC motif ligand 2 (CCL2) epigenetically silences via histone methylation both major histocompatibility complex class I (MHC-I) and the chemokine CCL2, resulting in exclusion of SCLC tumors from CD8+ T-cell and macrophage infiltration. Significantly, targeting EZH2 with small molecule inhibitors induces non-NE states with higher immunogenicity (29,30). In a similar fashion, lysine-specific demethylase 1 (LSD1) represses the expression of MHC-I and other antigen presentation pathway components, while its inhibition sensitizes SCLC tumors to immune checkpoint inhibitors (ICIs) in preclinical models by causing increased CD8+ T-cell infiltration (31). Beyond epigenetic silencing, defects in innate immune sensing also contribute to immune evasion in SCLC. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, responsible for cytosolic DNA sensing and type I interferon (IFN) induction critical for innate immune responses, is markedly downregulated in neuroendocrine (NE) SCLC. Their expression loss renders innate immunity defective and thus contributes to immunosuppression that allows for SCLC to progress and metastasize (32). Reactivation of STING via small molecule compounds such as histone deacetylase inhibitors (HDACis) may represent a plausible therapeutic strategy to boost innate immunity and immune infiltration in SCLC (33). In parallel with these intrinsic and innate immune defects, the metabolic landscape of the tumor microenvironment (TME) further impairs anti-tumor immunity. In the TME, tumor metabolism is also a key factor affecting immune characteristics. Although most solid tumors exhibit the Warburg effect with relatively mild lactate accumulation, massive lactate accumulation in SCLC leads to severe acidification of the microenvironment. A recent study identifies the lactate dehydrogenase (LDH)-H3K18La-Nur77 axis as a novel epigenetic mechanism in SCLC, where lactate-induced histone H3K18 lactylation in naïve CD8+ T-cells induces tonic T-cell receptor signaling, impairing antigen recognition and preventing effective anti-tumor activity, thus contributing to immune escape (34). Beyond cellular components, the neural microenvironment also plays a role in shaping SCLC progression and resistance. Research demonstrates that tumor-associated neurons release neurotransmitters such as acetylcholine and glutamate, which directly activate corresponding receptors on SCLC cells, promoting tumor growth, invasion, and conferring resistance to chemotherapy. This “neural addiction” represents a novel mechanism of immune evasion. This finding suggests that ZFHX3 mutation may serve as a potential predictive biomarker for immunotherapy benefit. ZFHX3 mutation is closely associated with immune-hot subtype features and positively correlates with the expression of antigen presentation-related genes in multi-omics analyses (27), as well as therapeutic resistance, offering potential targets for combination therapy (35,36). SCLC generally exhibits severe antigen presentation defects, driven by mechanisms such as MHC-I gene methylation, LSD1-mediated histone modification, low MHC molecule expression, and HMGB3-mediated abnormal cell junctions, further exacerbating tumor immune escape (27,37). Burr et al. (29) reported that transcriptional silencing of the MHC-I antigen processing pathway in SCLC promoted evasion of T-cell-mediated antitumor immunity. Spatial heterogeneity intensifies the “regionalization” of immunosuppression and weakens treatment effects (38). Spatial biology studies have shown that tumor tissues contain “immune desert areas”, “immune exhaustion areas”, and “immune activation areas” (39). Immune deserts, which constitute approximately 50% of cases, are defined by a near-complete absence of CD8+ T-cell infiltration. Instead, these regions are densely populated by MDSCs and typically exhibit negative PD-L1 expression (26). Immune therapy is completely ineffective in these areas. The immune exhaustion area (35%) contains CD8+ T-cells that highly express PD-1 and are surrounded by Tregs, showing only partial response to PD-1/PD-L1 inhibitor combined with chemotherapy (40). The immune activation area (15%) has M1-like macrophages activating CD8+ T-cells through tumor antigen presentation. This specific immune signature is highly predictive of clinical outcome, with patients achieving response rates above 60% to monotherapy (41). This spatial heterogeneity results in potentially distinct treatment effects across different tumor lesions even in the same patient (42). Hiatt et al. (43) reported inhibited EZH2 or LSD1 expression, which significantly upregulated MHC-I expression in SCLC, resulting in increased CD8+ T-cell infiltration and an enhanced therapeutic response to PD-1 inhibitor treatment. The SCLC immune microenvironment is closely associated with molecular subtypes. The SCLC-I subtype has most abundant immune infiltration and high PD-L1 expression levels, showing best response to immunotherapy. In contrast, the SCLC-A/N subtypes have strongest immunosuppressive effects and poor response to immunotherapy. Subtype directly determines potential for immunotherapy benefit (44). Simplified overview of tumor-immune microenvironment of SCLC was shown in Figure 1. Simplified overview of tumor-immune microenvironment of SCLC. SCLC exhibits a non-uniform immune phenotype and present highly heterogeneity including both lineage plasticity and evolution causing “cold” and/or “hot” immune states, alongside distinct molecular subtypes. Predictive biomarkers such as multi-omics-based subtype, SLFN11 status, and immune cell infiltration would guide therapeutic strategies of chemotherapy, targeted therapy, and immunotherapy. Arezo, atezolizumab; DC, dendritic cell; EP, etoposide and platinum; ES-SCLC, extensive-stage SCLC; GRN, granulin; LS-SCLC, limited-stage SCLC; NE, neuroendocrine; NMF, non-negative matrix factorization; SCLC, small cell lung cancer; TAM, tumor-associated macrophage; TCR, T-cell receptor. In the TME, tumor metabolism is also a key factor affecting immune characteristics (45). Although most solid tumors exhibit the “Warburg effect” (46), where tumor cells prefer anaerobic glycolysis, accumulation of lactic acid is relatively mild. Consequently, microenvironmental pH remains relatively stable, minimizing the functional impairment of infiltrating immune cells (47). In SCLC, massive lactate accumulation leads to severe acidification of the microenvironment (lower pH), which directly impairs the antigen-presenting capacity of DCs and compromises CD8+ T-cell activation (48). Additionally, MYC-amplified subtype consumes large amounts of amino acids (such as tryptophan and arginine) in TME, further impairing immune cell proliferation and effector functions (49). Most solid tumors have favorable response rates (30–50%) to ICIs, and a subset of these patients can achieve durable long-term remission (50). In contrast, the overall response rate to immunotherapy in SCLC is low, at only 10–20%, with only SCLC-I subtype and high tumor mutational burden (TMB) subtypes showing some response to immunotherapy (51). Most subtypes develop resistance to ICIs as a direct consequence of their “cold tumor” characteristics, which include insufficient immune cell infiltration and defective antigen presentation (52). The core regulatory molecules in most solid tumors are classical immune checkpoints such as PD-L1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and immunosuppressive cytokines like transforming growth factor-β (TGF-β) and interleukin-10 (IL-10), with relatively clear regulatory mechanisms (53). LS-SCLC tumor tissue omics research reveals biomarkers for immunotherapy LS-SCLC accounts for approximately 30% of all SCLC cases. Surgical resection combined with adjuvant therapy is main treatment model, but the postoperative recurrence rate remains as high as 60–70% (54). In recent years, immunotherapy has achieved breakthroughs in the field of LS-SCLC, but only a portion of patients benefit. Such limited efficacy is largely driven by the profound heterogeneity of tumor immune microenvironment in LS-SCLC, emphasizing the importance of omics studies to clarify its heterogeneity (55). Liu et al. (27) performed a prospective study of 112 operable LS-SCLC patients, integrating whole-exome sequencing (WES), RNA sequencing (RNA-seq), and tandem mass tag (TMT) proteomics. They stratified SCLC into three immune subtypes: the immune-cold subtype (79%) featured low immune infiltration, high-NE scores, and poor prognosis; the paracancer-enriched subtype (7%) exhibited immunological traits analogous to normal lung tissue, with its clinical relevance yet to be validated; the immune-hot subtype (14%) was enriched in cytotoxic immune cells, with upregulated immunosuppressive molecules and MHC genes, and thus showed greater potential to respond to immunotherapy. Additionally, non-negative matrix factorization (NMF) clustering identified four multi-omics subtypes with distinct drug sensitivities: NMF1 was sensitive to EP chemotherapy (etoposide and platinum) and ATR/topoisomerase I inhibitors, NMF2 was sensitive to DLL3-targeted ADCs, NMF3 was sensitive to anlotinib, and NMF4 was sensitive to aurora kinase inhibitors. Furthermore, elevated HMGB3 expression correlated with poor survival outcomes in patients with LS-SCLC, whereas ZFHX3 mutations were associated with favorable survival profiles. The major pathological response rate reached 100% in the mutation group, which was significantly higher than that observed in the wild-type group when treated with neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy. This study overcomes the challenge of difficult precise classification and target identification in SCLC, which previously relied on genomic mutations. By analyzing the proteome, researchers constructed a large-scale SCLC proteogenomic map. The subtype-specific treatment strategies and markers proposed by this research provide clinical evidence for the transition of SCLC treatment from “one-size-fits-all therapy” to “personalized precision therapy” (27). The study further delineated the drug sensitivity profiles of each NMF subtype based on in vitro data: the NMF1 subtype is enriched in cell cycle and DNA damage pathways and sensitive to ATR inhibitors and topoisomerase I inhibitors; the NMF2 subtype was characterized by high DLL3 expression and suitable for DLL3-targeted ADC therapy; the NMF3 subtype exhibited high receptor tyrosine kinase signaling activity and was sensitive to targeted therapy such as anlotinib; the NMF4 subtype showed high MYC expression and was sensitive to aurora kinase inhibitors (27). Chen et al. (55) analyzed 165 surgical specimens, integrating spatial imaging technology CO-Detection by indEXing (CODEX), multi-omics analysis [WES, RNA-seq, single-cell RNA-seq (scRNA-seq)], and traditional pathological validation. They innovatively developed the ColonyMap algorithm to quantify spatial cell interaction patterns and discovered a specific spatial immune structure called “MT2 niche”. This structure is mainly composed of CD8+ T-cells, NK T-cells, and M1-like inflammatory, IFN-activated macrophages, and is predominantly located at the tumor-stroma boundary. The study confirmed that LS-SCLC patients with a larger MT2 niche area had significantly prolonged OS, and this prognostic value was independent of overall tumor immune infiltration level. Further mechanism analysis revealed that CD8+ T-cells within the MT2 niche maintained lower expression levels of immune exhaustion markers, whereas macrophages in this region exhibited significantly enhanced antigen-presenting capacity, as evidenced by high CD11c expression. More importantly, this structure can be extended to predict response to ICI treatment in ES-SCLC patients. Patients with MT2 niches rich in M1-like macrophages (high M1-MT2 ratio) showed significantly improved disease control rate (DCR) after ICI treatment (55). Integrative analysis of spatial transcriptomics and proteomics further revealed that macrophages within the MT2 niche highly expressed M1-polarization-associated proteins, whereas tumor cells in adjacent areas showed low expression of NE-related proteins, a spatial distribution pattern consistent with the transcriptomically defined immune-hot subtype, confirming the concordance between spatial and molecular omics data (55). A study on SCLC efficacy biomarkers further discovered that SLFN11 (DNA/RNA helicase) was a key marker for SCLC treatment sensitivity. SLFN11 exhibits a specific expression pattern in SCLC molecular subtypes: highly expressed in multi-positive tumor cells enriched regions of the SCLC-A subtype and also highly expressed in the SCLC-N subtype. At the functional level, SLFN11 can significantly enhance sensitivity of tumor cells to DNA-damaging drugs (such as platinum-based chemotherapy) and PARP inhibitors (PARPi) by regulating DNA damage repair processes. This suggests that it may potentially serve as a predictive marker for the efficacy of PARPi treatment in SCLC patients, providing a reference for the formulation of subtype-specific targeted treatment plans for SCLC (27). Mechanistically, SLFN11 sensitizes tumor cells to DNA damage, which, when combined with PARP inhibition, leads to increased cytosolic DNA accumulation, activation of the cGAS-STING pathway, and subsequent type I IFN production, thereby enhancing anti-tumor immunity and potentially synergizing with immune checkpoint blockade. In ES-SCLC, SLFN11 expression positively correlates with the effector T-cell to tumor-associated macrophage (TAM) ratio, suggesting that it may indirectly influence T-cell infiltration and function by modulating DNA damage sensing pathways in the immune microenvironment (56). Gay et al. (44) used NMF to analyze RNA-seq data from 81 surgically resected SCLC samples and identified a subgroup of SCLC with low expression of three transcription factors, ASCL1, NEUROD1, and POU2F3, which was defined as SCLC-I subtype. SCLC overall has a low response rate to ICI, possibly due to low infiltration of immune cells, particularly cytotoxic T-cells. Using the CIBERSORT with X cell type refinement deconvolution method, SCLC-I subtype was shown to have the highest total immune infiltration and cytotoxic score, with a significant increase in the absolute number of immune cell populations (including T-cells, NK-cells, and macrophages), compared with other SCLC subtypes (44). Although LS-SCLC patients account for 30% of SCLC cases, most multi-omics studies focus on LS-SCLC due to high tissue volume requirements. Therefore, we have a relatively in-depth understanding of microenvironmental characteristics of early-stage SCLC. With immunotherapy combined with chemotherapy becoming the consolidation treatment for LS-SCLC, these discoveries regarding immune microenvironment may provide preliminary evidence for patient stratification in LS-SCLC immunotherapy. In the future, more clinical trial biomarker studies may provide effective evidence for prolonging the survival of limited-stage patients. However, for ES-SCLC with a 5-year survival rate <2%, the understanding of its microenvironmental characteristics remains limited (57). Research progress on the immune microenvironment of treatment-naive ES-SCLC Zhou et al. (58) enrolled patients with SCLC patients in study, which comprised three core cohorts—112 operable cases, 165 locally extensive-stage cases, and 314 cross-population validation cases—and covered SCLC patients with different smoking statuses, stages, and treatment histories. Combining multi-dimensional analyses such as single-cell sequencing, WES and spatial proteomics (SP), the study found that 79% of patients had minimal infiltration of effector immune cells (such as CD8+ T-cells and NK-cells) within the tumor, which were only distributed at tumor margin. The proportions of MDSCs (18.2%) and Tregs (9.5%) were significantly higher than those in NSCLC. MHC-I gene silencing was observed in 80%-90% of patients, with DCs functional exhaustion and impaired immune response. Early-stage patients had more granzyme B+CD8+ T-cells and tertiary lymphoid structures (TLS) than late-stage patients. Treatment responders complete response/partial response (CR/PR) showed significantly better levels of immune cell infiltration, TLS quantity, and MHC pathway activity compared to non-responders stable disease/progressive disease (SD/PD). ScRNA-seq identified 7 cell types and 58 cell subtypes, including endothelial cells, fibroblasts/fibroblast-like cells, alveolar type I/II (AT1/2)/basal/ciliated cells, NE/cancer cells, macrophages and monocytes, B-cells, and T/NK-cells. The researchers first analyzed immune cell characteristics and found that among 27 untreated tumors, 19 had an immune cell proportion <10%, 7 had 10–50%, and 1 had >50%, illustrating the heterogeneity of immune microenvironment. The researchers subsequently conducted more in-depth analyses of macrophages, B-cells, and T/NK-cells. Combined single-cell sequencing and SP revealed that plasma cell subsets enriched in treatment responders were spatially co-localized with MHC pathway activity, whereas immunosuppressive macrophage subsets were predominantly located at the tumor margin. This spatial distribution pattern was consistent with transcriptomically identified immune activation/suppression signals, providing an integrated perspective on the cellular and spatial basis of treatment response (58). Focusing on the myeloid compartment, seven macrophage subsets were identified. Analysis of these subsets revealed a dynamic shift following neoadjuvant therapy, characterized by depletion of immunosuppressive subsets and simultaneous enrichment of pro-inflammatory/immune-stimulatory subsets. T/NK-cells were divided into 14 subtypes, with increased NK-cell activity markers and decreased Tregs after treatment. B-cells were classified into nine distinct subsets. Notably, treatment responders exhibited a higher abundance of plasma cell subsets, which may contribute to anti-tumor immune response. Regarding the tumor cell compartment, ASCL1+/MKI67+ (proliferative) and ASCL1+/CRIP2+ (mature NE) populations collectively accounted for 74.38% of total, confirming predominant NE nature of tumors. All subtypes contained ASCL1+SOX1+ stem cell-like clusters, whose proportion increased after treatment; these clusters may be a key factor in disease recurrence. The detection rate of FAK splice variants was higher in pure SCLC than in mixed-type SCLC. Reverse transcription-polymerase chain reaction and Sanger sequencing identified three variants: FAK6, FAK7, and FAK6,7. Box6/Box7 splicing activity was significantly higher in tumor tissue than in adjacent tissue. Patients carrying variants (especially FAK6,7 compound variants) had significantly shorter OS than wild-type patients (P=0.029), and these variants were mainly enriched in SCLC-A/N subtypes, potentially serving as specific markers for these two subtypes. FAK variants, especially FAK6 and FAK7, conferred increased sensitivity to FAK inhibitors in SCLC organoids, highlighting their potential as biomarkers for drug efficacy. A post-hoc analysis of IMpower133 study evaluated pretreatment tumor tissue RNA-seq data from 271 patients. By combining traditional SCLC-A/N/P/I subtypes with immune infiltration status, NMF clustering identified four subtypes: NMF1/SCLC-N and NMF2/SCLC-A showed significant immunosuppressive characteristics and poor response to atezolizumab combined with EC regimen; NMF3/SCLC-I-NE (NE inflammatory type) had rich immune infiltration and the best response (median-OS of 16.37 vs. 8.63 months, HR =0.45); NMF4/SCLC-I-nNE (non-NE inflammatory type) had moderate immune infiltration with intermediate efficacy. The study also found that effector T-cell/TAM ratio was the optimal efficacy predictor, with patients having high ratio showing significantly prolonged OS (HR =0.26), while those with low ratio showed no significant benefit (HR =0.85) (15). This ratio captures the functional balance between pro-inflammatory cytotoxic T-cells and immunosuppressive myeloid cells. A high ratio favors an ‘immune-hot’ state conducive to ICI response, while a low ratio, even with high T-cell numbers, indicates a suppressive milieu dominated byTAMs that can blunt the effect of immunotherapy through the secretion of immunosuppressive cytokines such as IL-10 and TGF-β, and the expression of immune checkpoint ligands. This ratio positively correlates with SLFN11 expression levels, suggesting that DNA repair status may modulate this balance by influencing tumor immunogenicity (15,59). A 2025 transcriptional regulatory network analysis based on this study identified granulin (GRN) as a core hub gene associated with resistance. The GRN high-expression group mostly consisted of non-NE subtypes (low NE marker expression), with low proportions of effector T-cells and B-cells, and increased proportions of immunosuppressive cells, failing to benefit from atezolizumab plus EC regimen. The GRN low-expression group mostly consisted of NE subtypes (high NE marker expression), with high proportions of effector T-cells and B-cells and high expression of antigen presentation machinery (APM)-related genes, showing significantly prolonged median PFS (7.2 vs. 3.1 months, P=0.004) and median OS (16.5 vs. 8.5 months, P=0.003) (59). Mechanistic studies suggest that GRN may promote an immunosuppressive microenvironment by recruiting and polarizing TAMs towards an M2-like phenotype, thereby inhibiting T-cell effector function and contributing to immunotherapy resistance. High GRN expression is closely associated with non-NE subtypes, which frequently exhibit MYC amplification and antigen presentation defects, suggesting that GRN may serve as a key molecule linking tumor-intrinsic plasticity to an immunosuppressive microenvironment. GRN expression is negatively correlated with ZFHX3, further suggesting that combinations of different biomarkers may collectively shape the immune phenotype of SCLC (59). ASTRUM-005 study was a phase III multicenter randomized controlled study evaluating serplulimab combined with chemotherapy as first-line treatment for ES-SCLC. Peripheral blood proteomic analysis was performed on patients using the Olink®Explore 3072 platform. The study enrolled 168 patients and developed a protein signature model based on 15 differentially expressed proteins, including ENPP2, GAL, and CCDC50. Patients with a high model score who received serplulimab combined with chemotherapy had significantly longer median PFS (7.9 vs. 4.4 months, P<0.001) and median OS (17.2 vs. 9.1 months, P<0.001). The predicted area under the receiver operating characteristic (ROC) curve (AUC) in training and validation sets reached 0.982 and 0.918, respectively, demonstrating great potential for clinical application (60). The SWOG S1929 study included 309 ES-SCLC patients to evaluate the efficacy of atezolizumab monotherapy or combined with talazoparib. Data showed that SLFN11 expression levels were significantly associated with efficacy. SLFN11-positive (H-score ≥1) patients had significantly better PFS (HR =0.71) and OS (HR =0.70). Using H-score ≥100 as threshold, the PFS benefit was more significant in atezolizumab combined with talazoparib group (HR =0.64), but a higher threshold (≥200) had no additional predictive value. Consequently, the SWOG S2409 (PRISM) study has incorporated SLFN11 as a pretreatment stratification factor, assigning patients to different treatment regimens based on NE subtype and SLFN11 status. For instance, SLFN11-positive patients receive immunotherapy combined with PARPi, whereas SLFN11-negative patients receive immunotherapy combined with ATR inhibitors. This design illustrates the advancement of SLFN11 from a research marker to a clinically applicable biomarker (61). For ES-SCLC, the EXTENTORCH trial examined clinical efficacy of first-line treatment with toripalimab in combination with chemotherapy. WES data from tumor tissues of 300 patients identified several DNA-level biomarkers associated with efficacy: patients carrying HLA-A11+HLA-B62− haplotype had significantly longer survival (median PFS: 7.03 vs. 5.55 months, P=0.05; median OS: 18.43 vs. 12.94 months, P=0.04). The mechanism involves optimized antigen presentation, in which HLA-A11 potently binds common SCLC antigens while HLA-B62 mitigates competition from inhibitory peptides. Patients with wild-type KMT2D/COL4A4 had better survival (median PFS: 5.85 vs. 5.45 months, P=0.0004; median OS: 16.23 vs. 13.09 months, P=0.004), as wild-type KMT2D maintains antigen presentation pathway integrity and wild-type COL4A4 inhibits stromal barrier formation. Patients with CTNNA2/SCN4A mutations had significantly prolonged survival (median PFS: 14.98 vs. 5.65 months, P=0.009; median OS: 22.23 vs. 14.59 months, P=0.006), attributed to the enhanced antigen release and tumor immunogenicity induced by these alterations. Patients with wild-type focal adhesion/integrin pathway (COL1A1, COL4A4, ITGA8, etc.) had better survival (median PFS: 6.24 vs. 4.14 months, P<0.0001; median OS: 16.56 vs. 10.81 months, P<0.0001), as pathway mutations induce the formation of an extracellular matrix (ECM) barrier and inhibit T-cell function. Additionally, patients with low intratumoral heterogeneity (ITH) (score <29) showed improved survival (median PFS: 6.90 vs. 5.59 months, P=0.05; median OS: 18.86 vs. 13.16 months, P=0.01). Reduced ITH decreases antigen diversity, facilitating T-cell-mediated cytotoxicity. These biomarkers’ functions are directly related to antigen presentation, immune cell activation, and stromal barrier remodeling in SCLC immune microenvironment (62). Gay et al. performed a retrospective analysis of the IMpower133 trial and tumor tissue dataset analysis, found that SCLC-I patients derived the greatest benefit from immunotherapy. These patients exhibited increased infiltration of T-cell and NK-cell infiltration in tumor tissues, suggesting that NK-cell infiltration and activation may be associated with immunotherapy response in SCLC patients (44). A retrospective observational study found that among ES-SCLC patients receiving immunotherapy combined with chemotherapy, median PFS was longer in the group with normal baseline NK-cell levels than in the group with low baseline NK-cell levels (7.0 vs. 4.6 months; HR =0.17; P<0.0001), but this was not associated with OS (14.9 vs. 10.3 months; HR =0.55; P=0.171). Dynamic changes in peripheral NK-cells after immunotherapy combined with chemotherapy can also serve as predictive indicators of efficacy. Patients with increased NK-cell percentages between baseline and best response, as well as between baseline and disease progression, had better median PFS and OS (63). Schmälter et al. analyzed changes in peripheral T, B, and NK lymphocytes and their subsets in stage IV SCLC patients treated with carboplatin, etoposide, and atezolizumab. The results showed that reduced Th17 cells after treatment were associated with better cumulative survival, suggesting Th17 as a potential efficacy predictor. The study further demonstrated that SCLC patients had higher Th17 cell counts than healthy individuals. As a subset of pro-inflammatory CD4+ T-cells, Th17 cells may be involved in SCLC pathogenesis (64). Study by Kanemura et al. showed that PD-L1 expression, CD8+ T-cells infiltration, and high frameshift antigen load can predict ICI benefit in ES-SCLC. Tumors were classified as inflamed or non-inflamed based on PD-L1 expression levels and CD8+ tumor-infiltrating lymphocyte density. The median PFS for inflamed (n=7) and non-inflamed (n=56) tumors was 10.8 and 5.1 months, respectively (HR =0.26) (65). The IMpower133 clinical study found that SCLC-I subtype had a significant OS benefit in atezolizumab combined with etoposide + cisplatin group [HR =0.566; 95% confidence interval (CI): 0.321–0.998]. To investigate unique treatment vulnerabilities among different subtypes, eauthors utilized publicly available in vitro drug response data of SCLC cell lines against more than 500 drugs. They found that the SCLC-P subtype was most sensitive to standard cisplatin therapy, while SCLC-I subtype was resistant to cisplatin therapy. The authors selected two ASCL1-dominant CDX models (MDA-SC53 and MDA-SC68) sensitive to platinum-based chemotherapy. The CDX models were first with cisplatin until maximum response was achieved, and single-cell sequencing was subsequently performed on the recurrent tumor tissues. Recurrent model cells continuously acquired MHC class-II gene expression, which was only expressed in SCLC-I cells and had higher EMT scores, showing typical SCLC-I subtype characteristics. These single-cell analyses indicated that cisplatin resistance coincides with the emergence of a population of cells representing SCLC-I subtype, which apparently originated from the original SCLC-A cells that had undergone subtype switching driven by fluctuating Notch pathway activation. In turn, these SCLC-I cells possess stem cell-like plasticity features, which may underlie the capacity of this minor cell population to drive the development of drug-resistant tumor phenotypes (44). In summary, research on tumor immune microenvironment in ES-SCLC patients has mostly focused on biomarkers for immunotherapy benefit. For ES-SCLC, immunotherapy combined with chemotherapy serves as the standard treatment, but only a small subset of patients derives benefits. Research on ES-SCLC immune microenvironment aims to understand immune characteristics while identifying clinically applicable biomarkers that can guide immunotherapy combined with chemotherapy. Despite current research progress, no clinically applicable biomarkers have been identified yet. However, biomarker exploration in clinical studies such as ASTRUM-005, EXTENTORCH, and IMpower133 has brought ES-SCLC immunotherapy biomarkers one step closer to clinical application. Integrating multi-omics analyses in ES-SCLC, an immune phenotype characterized by high effector T-cell signals and low TAM infiltration, has been validated as a robust predictor of significant survival benefit from PD-L1 blockade (15). Furthermore, SLFN11 has been prospectively validated in a randomized phase II trial as a predictive biomarker for improved PFS with PARPi (talazoparib) plus anti-PD-L1 maintenance therapy in ES-SCLC (61). These findings suggest that integrating multi-dimensional biomarkers (e.g., subtype, immune infiltration, DNA repair status) may represent a key direction for achieving precision immunotherapy in ES-SCLC. In the future, more biomarker exploration in clinical studies will accelerate the pace of clinical application (66). Key features of SCLC subtypes by NE status were shown in Table 1. Table 1Key features of SCLC subtypes by NE statusFeaturesNENon-NESCLC-ASCLC-NSCLC-PSCLC-IImmune phenotype“Cold” tumor“Cold” tumor–“Hot” tumorCD8+ T cell infiltrationPeritumoral only, sparseVery low, exhausted–Markedly increased, functionalNK cell infiltrationInsufficientVery low–Markedly increasedKey immune escape mechanismMHC-I methylationHMGB3-driven immune evasion–Minimal immune escapeKey immune-related markersHigh SLFN11 High SLFN11High POU2F3ZFHX3 mutationICI sensitivityLowLow–HighICI, immune checkpoint inhibitor; MHC-I, major histocompatibility complex class I; NE, neuroendocrine; NK, natural killer; SCLC, small cell lung cancer. Key features of SCLC subtypes by NE status ICI, immune checkpoint inhibitor; MHC-I, major histocompatibility complex class I; NE, neuroendocrine; NK, natural killer; SCLC, small cell lung cancer. Immune microenvironment characteristics of chemo resistant SCLC There are two main mechanisms of resistance to immunotherapy in SCLC: tumor-intrinsic mechanisms and tumor-extrinsic mechanisms. Intrinsic mechanisms primarily involve antigen presentation defects (such as decreased expression of MHC-I and β2-microglobulin (β2-MG), key gene mutations, and epigenetic changes (abnormal activation of EZH2 and LSD1), which collectively impair the ability of tumor cells to be recognized and eliminated by immune system. Additionally, DLL3, a unique marker of SCLC, further reduces tumor immunogenicity by inhibiting the STING pathway. Akbay et al. (67) reported that 6TdG, a nucleoside analog with a high affinity for telomerase, can promote antitumor immunity by activating STING and type-I IFN signaling, leading to tumor recognition by immune system. Extrinsic mechanisms focus on the complex role of TME, including sparse tumor-infiltrating lymphocytes (TILs), functionally active immunosuppressive cells (such as Tregs and MDSCs), abnormal angiogenesis, and suppressive regulation of immune responses by gut microbiome (68). ADCs currently represent new hope for treatment of advanced SCLC. ADCs achieve specific killing of tumor cells by linking monoclonal antibodies to cytotoxic drugs. Upon induction of tumor cell apoptosis, ADCs release damage-associated molecular patterns (DAMPs), including surface-exposed calreticulin [chemoradiotherapy (CRT)] that sends a “phagocytic signal” to DCs, and ATP with high-mobility group box 1 protein (HMGB1) that recruit DCs. Immunogenic cell death (ICD) enhances the antigen-presenting efficiency of DCs by three- to four-fold, activating CD8+ T-cells and establishing tumor-specific immune memory. ADCs convert “immune-cold” tumors into “immune-hot” tumors by depleting immunosuppressive components, such as Tregs and M2-type macrophages, while promoting the infiltration of effector cells, including CD8+ T-cells and NK-cells. In patients receiving ADCs treatment, intratumorally CD8+ T-cell density increased by 2–3-fold compared to pretreatment, and most of these cells were “non-exhausted” (PD-1−Tim-3−). The Fc segment of ADCs antibodies can bind to Fc receptors on surface of immune cells, triggering antibody-dependent cellular cytotoxicity (ADCC), recruiting NK-cells to release perforin and granzyme, directly killing tumor cells, antibody-dependent cellular phagocytosis (ADCP) can promote macrophages to phagocytose apoptotic tumor cells, further releasing tumor antigens. Furthermore, it triggers complement-dependent cytotoxicity (CDC), which activates the complement cascade to form membrane attack complexes (MAC) and lyse tumor cells. Studies have shown that in ADCs targeting HER2, B7-H3, and other targets, the killing effect mediated by ADCC/ADCP accounts for 20–30% of total efficacy (69). Currently, well-studied ADCs targets in SCLC include DLL3, B7-H3, SEZ6, TROP2, etc., with significant differences in expression of each target among SCLC subtypes. DLL3 is mainly highly expressed in SCLC-A subtype, accounting for approximately 52% (70). SEZ6 is highly expressed in SCLC-A and SCLC-N subtypes (71), with higher expression levels in male patients than in female patients, and 50% of SCLC-P subtypes also highly express SEZ6 (72). B7-H3 (CD276) belongs to B7 immune checkpoint superfamily, can inhibit T-cell activation and proliferation, weakening anti-tumor immunity (73). Its high expression is mainly seen in non-NE subtypes, accounting for approximately 45% (74). TROP2 is widely expressed in SCLC but with low specificity (75). Tarlatamab is a bispecific T-cell engager targeting DLL3 that has shown efficacy in relapsed/refractory (R/R) SCLC, but acquired resistance remains a pressing issue (76). A case report analyzed one ES-SCLC patient who progressed after tarlatamab treatment and found that resistance mechanism was associated with the following factors: SCLC subtype transformation: upregulation of SCLC-A and N subtype-related genes before treatment, with enhanced expression of SCLC-P and I subtype-related genes after treatment, showing a significant gene expression shift; Notch signaling pathway upregulation: upregulation of Notch family gene expression after treatment, downregulation of Delta-like family genes (including DLL3),with tumors exhibiting Notch “receiver” characteristics, preventing effective binding of tarlatamab to DLL3; T-cell functional exhaustion: increased expression of T-cell-related gene markers (CCR7, GZMB, etc.) and immunohistochemical markers (CD3, CD4, CD8, PD-L1) after treatment, but termination of tarlatamab-mediated T-cell killing effect was terinated. Additionally, the DAREON-8 study evaluated the efficacy of novel DLL3/CD3 bispecific antibody obrixtamig and found that patients with extrapulmonary NE carcinoma with high DLL3 expression (≥50% tumor cell positivity) had significantly better ORR, DCR, and median duration of response (mDOR) than those with low expression, further confirming that DLL3 expression level is a key marker for DLL3-targeted drugs (77). B7-H3 can serve as both an ADCs target and an immunotherapy resistance marker (78). A study found that among ES-SCLC patients treated with chemotherapy combined with ICI, those with high B7-H3 expression had significantly shorter median PFS (4.3 vs. 5.4 months, P=0.03) and median OS (8.4 vs. 14.2 months, P=0.09, not statistically significant) compared to those with low expression, while no significant difference was observed in the chemotherapy-only group. Mechanistically, B7-H3 drives resistance by inhibiting CD8+ T-cell effector functions, rendering tumors in a state of “T-cell infiltration but functional dysfunction” (79). Immune microenvironment characteristics of never-smoker SCLC (nsSCLC) NsSCLC accounts for 3–6% of all SCLC cases, and its pathogenesis and immune microenvironment differ significantly from smoking-related SCLC (sSCLC) (80). The overall immune infiltration level of nsSCLC was significantly lower than that of sSCLC, with lower proportions of effector T-cells and DCs were revealed by a multi-omics study involving never-smoker or light-smoker (≤10 pack-years) SCLC patients with double-positive RB1 and TP53. The study classified nsSCLC into two categories: the characteristics of category 1 retains the functions of RB1 and TP53, accompanied by chromosomal fragmentation and highly expresses target proteins such as DLL3 and SEZ6 of the ADC. The characteristics of category 2 is characterized with both RB1 and TP53 inactivation, and conform to the situation of “adenocarcinoma transforming into SCLC”. The median OS of nsSCLC was 22 months, which was between sSCLC (16 months) and lung carcinoid (184 months) (81). It is important to note that these findings were based on a relatively small cohort (n=20) and should be interpreted with caution. The conclusions regarding the immune characteristics and classification of nsSCLC warrant further validation in larger, prospective studies. Conclusions In this review, we have comprehensively explored the latest advancements in SCLC immune microenvironment research, integrating findings from multi-omics, spatial biology and clinical trials. Despite these advances, several knowledge gaps and challenges remain necessitating future research. First, clinical translation of molecular subtypes is a priority. While SWOG S2409 represents a pioneering effort in subtype-adaptive trials, harmonizing classification methodologies (e.g., standardized immunohistochemistry panels for ASCL1, NEUROD1, POU2F3) and developing non-invasive liquid biopsy assays to dynamically monitor subtype switching during treatment are crucial next steps (82,83). Second, elucidating mechanisms of immunotherapy resistance requires a deeper, integrated understanding. Future studies should focus on the interplay between tumor-intrinsic factors (e.g., MYC amplification, MHC-I loss) and the TME using advanced models such as patient-derived organoids (PDOs) and humanized mice (84,85). Third, optimizing combination strategies beyond PD-(L)1 blockade is essential. This includes not only exploring rational combinations like epigenetic modulators (LSD1/EZH2 inhibitors) with ICIs (86), but also determining the optimal sequencing and patient selection for novel agents like DLL3-targeted T-cell engagers (13) and ADCs (9). Finally, the integration of artificial intelligence and multi-dimensional data will be instrumental in developing robust predictive models for patient stratification and guiding adaptive treatment strategies. Ultimately, moving from a ‘one-size-fits-all’ approach to a personalized, biomarker-driven, and dynamically monitored immunotherapy paradigm will be key to overcoming the longstanding therapeutic plateau in SCLC. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0320/prf